Literature DB >> 10195630

Evaluation of the stability and immunogenicity of autoclaved and nonautoclaved preparations of a vaccine against American tegumentary leishmaniasis.

P M De Luca1, W Mayrink, C R Alves, S G Coutinho, M P Oliveira, A L Bertho, V P Toledo, C A Costa, O Genaro, S C Mendonça.   

Abstract

This study was designed to evaluate the immunogenicity of autoclaved and nonautoclaved preparations of a vaccine composed of whole antigens from killed promastigotes of Leishmania amazonensis. Leishmanin skin-test (LST)-negative volunteers were immunized with either autoclaved or nonautoclaved vaccine preparations (32 and 36 subjects, respectively) that had been maintained at 4 degrees C for one year before the onset of this trial. Immunological tests were performed two days before and 40 days after vaccination. The LST conversion rates induced by the autoclaved and nonautoclaved vaccines were significantly different: 59% and 83%, respectively. Leishmania antigen-stimulated proliferative responses of peripheral blood mononuclear cells (PBMC) were significantly higher after vaccination than before vaccination in both groups. The CD8+ subset was predominant over the CD4+ subset among the leishmania-reactive cells after vaccination in both groups. The production of IFN-gamma by the leishmania antigen-stimulated PBMC was significantly higher after vaccination than before vaccination in the group receiving the nonautoclaved vaccine but not in the autoclaved vaccine group. IL-2 was found both before and after vaccination with no differences between its levels in these time points in either group. IL-4 was not detected for either group during the study period.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10195630     DOI: 10.1016/s0264-410x(98)00338-7

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  22 in total

1.  In vitro responses of human peripheral blood mononuclear cells to whole-cell, particulate and soluble extracts of Leishmania promastigotes.

Authors:  E Telino; P M De Luca; D C S Matos; R B Azeredo-Coutinho; M N Meirelles; F Conceição-Silva; A Schubach; S C F Mendonça
Journal:  Clin Exp Immunol       Date:  2006-02       Impact factor: 4.330

2.  Immunization against leishmaniasis by PLGA nanospheres encapsulated with autoclaved Leishmania major (ALM) and CpG-ODN.

Authors:  Mohsen Tafaghodi; Ali Khamesipour; Mahmoud R Jaafari
Journal:  Parasitol Res       Date:  2010-12-02       Impact factor: 2.289

Review 3.  Leishmaniasis: current status of vaccine development.

Authors:  E Handman
Journal:  Clin Microbiol Rev       Date:  2001-04       Impact factor: 26.132

4.  Vervet monkeys vaccinated with killed Leishmania major parasites and interleukin-12 develop a type 1 immune response but are not protected against challenge infection.

Authors:  M M Gicheru; J O Olobo; C O Anjili; A S Orago; F Modabber; P Scott
Journal:  Infect Immun       Date:  2001-01       Impact factor: 3.441

5.  T-cell-mediated immune responses in patients with cutaneous or mucosal leishmaniasis: long-term evaluation after therapy.

Authors:  Alda Maria Da-Cruz; Rita Bittar; Marise Mattos; Manuel P Oliveira-Neto; Ricardo Nogueira; Vanessa Pinho-Ribeiro; Rilza Beatriz Azeredo-Coutinho; Sergio G Coutinho
Journal:  Clin Diagn Lab Immunol       Date:  2002-03

6.  Devitalization of transgenic seed that preserves DNA and protein integrity.

Authors:  Barry W Schafer; Charles Q Cai; Shawna K Embrey; Rod A Herman; Ping Song
Journal:  J Biomol Tech       Date:  2008-12

7.  Contrasting human cytokine responses to promastigote whole-cell extract and the Leishmania analogue receptor for activated C kinase antigen of L. amazonensis in natural infection versus immunization.

Authors:  R B G Azeredo-Coutinho; D C S Matos; G G R Armôa; R M Maia; A Schubach; W Mayrink; S C F Mendonça
Journal:  Clin Exp Immunol       Date:  2008-07-08       Impact factor: 4.330

8.  DNA immunization with the gene encoding P4 nuclease of Leishmania amazonensis protects mice against cutaneous Leishmaniasis.

Authors:  Kimberly Campbell; Hong Diao; Jiaxiang Ji; Lynn Soong
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

9.  Role of Mycobacterium vaccae in the protection induced by first generation Leishmania vaccine against murine model of leishmaniasis.

Authors:  Hosein Keshavarz Valian; Lavinia Khoshabe Abdollah Kenedy; Mahmoud Nateghi Rostami; Akram Miramin Mohammadi; Ali Khamesipour
Journal:  Parasitol Res       Date:  2008-06       Impact factor: 2.289

Review 10.  Present status of antileishmanial vaccines.

Authors:  Monidipa Ghosh; Santu Bandyopadhyay
Journal:  Mol Cell Biochem       Date:  2003-11       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.